A comprehensive scientific review published on September 24, 2026, in the journal Developmental Medicine & Child Neurology finds no robust epidemiological evidence that taking paracetamol during pregnancy causes autism or attention deficit hyperactivity disorder (ADHD) in children.
Methodological Quality Influences Research Findings
The analysis reveals that the strength of the statistical association between prenatal paracetamol exposure and neurodevelopmental outcomes directly depends on study design and bias control. When the research team evaluated all available meta-analyses without quality restrictions, they observed a small statistical correlation between the common pain and fever medication and diagnoses of autism or ADHD. However, that signal weakened substantially and approached zero once investigators filtered for methodologically superior meta-analyses and studies carrying a low risk of bias.
Lead author Hoda Tayebi Hillali of the University of Santiago de Compostela in Spain notes that a widely debated topic demands strong evidence rather than headlines. According to Hillali, the apparent association between prenatal paracetamol exposure and neurodevelopmental conditions diminishes as the methodological quality of the underlying research increases.
Context From Recent Scientific Studies and Regulatory Actions
This large-scale evaluation arrives roughly one year after a prominent warning issued by the U.S. government under then-President Donald Trump in September 2025 regarding the analgesic. The administration’s focus prompted the U.S. Food and Drug Administration (FDA) to initiate a process to alter warning labels for the medication—marketed as acetaminophen in the United States—while simultaneously emphasizing that a causal link had not been proven.
The 2026 findings align with other recent investigations examining the issue. A sibling-control study published in June of the same year compared children sharing the same mother and found no indication that paracetamol use during pregnancy elevates the risk of autism or ADHD. Those authors concluded that connections identified in earlier, less rigorous studies likely stem from shared familial factors rather than the medication itself. An expansive review of 43 studies published in January 2026 similarly reported no evidence linking the active ingredient to autism, ADHD, or intellectual disabilities, reinforcing the conclusion that rigorous sibling comparisons contradict a causal relationship.
Related reading